Clinical Trial Update: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea [Phase 3]

View source ↗

Summary

Phase 3 master protocol evaluating tirzepatide in adults with obstructive sleep apnea (with obesity) has completed, and results were posted in 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Obstructive Sleep Apnea

Drugs mentioned

• Tirzepatide (tirzepatide)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Obstructive Sleep Apnea, Obesity | Phase 3 | Status: COMPLETED | Results posted: 2025-04-30